logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12661172 B1

PDFFull Text
Date of Patent:
Jun. 23, 2026

Filed:

Jun. 24, 2022

Instrument for therapeutically cytotoxically ablating parathyroidal tissue within a parathyroid gland

Applicant:

Alan N. Schwartz, Edmonds, WA (US);

Inventor:

Alan N. Schwartz, Edmonds, WA (US);

Assignee:
Attorney:

Leonid Kisselev

Primary Examiner:

Laura A Bouchelle

Assistant Examiner:

Sarah Dympna Grasmeder

Int. Cl.
CPC ...
A61B 18/06 (2006.01); A61B 18/02 (2006.01); A61B 18/14 (2006.01); A61M 5/00 (2006.01); A61M 5/14 (2006.01); A61M 5/168 (2006.01); A61M 5/32 (2006.01); A61N 1/00 (2006.01); A61N 2/00 (2006.01); A61N 5/00 (2006.01); A61N 5/10 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61B 18/04 (2006.01); A61B 90/00 (2016.01); A61M 25/00 (2006.01); A61N 1/40 (2006.01); A61N 5/06 (2006.01); A61N 7/02 (2006.01);
U.S. Cl.
CPC ...
A61B 18/06 (2013.01); A61B 18/02 (2013.01); A61B 18/1477 (2013.01); A61M 5/007 (2013.01); A61M 5/1407 (2013.01); A61M 5/168 (2013.01); A61M 5/32 (2013.01); A61N 1/00 (2013.01); A61N 2/004 (2013.01); A61N 5/00 (2013.01); A61N 5/1027 (2013.01); A61B 2017/00743 (2013.01); A61B 2018/00017 (2013.01); A61B 2018/00196 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00279 (2013.01); A61B 2018/00428 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00708 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00839 (2013.01); A61B 2018/00863 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/00994 (2013.01); A61B 2018/0262 (2013.01); A61B 2018/0293 (2013.01); A61B 2018/044 (2013.01); A61B 2018/1472 (2013.01); A61B 2090/378 (2016.02); A61B 2090/3908 (2016.02); A61B 2090/3966 (2016.02); A61B 2218/002 (2013.01); A61M 2025/0046 (2013.01); A61M 25/0068 (2013.01); A61N 1/406 (2013.01); A61N 5/062 (2013.01); A61N 2005/0626 (2013.01); A61N 2005/0635 (2013.01); A61N 2005/0659 (2013.01); A61N 2005/0661 (2013.01); A61N 7/02 (2013.01); A61N 2007/025 (2013.01);
Abstract

One embodiment provides a tightly targeted minimally invasive therapy (TTMIT) parathyroid tissue ablating instrument. A substance that cytotoxically ablates parathyroidal tissue during application in the parathyroidal tissue of therapeutically sufficient units of an electromagnetic energy having a frequency only ranging from ultraviolet to visible to near infrared. A substance delivery device is configured to introduce the substance into the parathyroidal tissue. An electromagnetic energy treatment device is configured to apply the therapeutically sufficient units of the electromagnetic energy within a thermal range that is non-cytotoxic to the parathyroidal tissue to the substance after the substance has been introduced by the substance delivery device. A sensor is configured to monitor activation of the substance as the therapeutically sufficient units of the electromagnetic energy are applied. The electromagnetic energy treatment device is further configured to modulate applying the therapeutically sufficient units of the electromagnetic energy once the substance has been activated.

Find Patent Forward Citations

Loading…